FDA Guides On Bioequivalence Studies And COVID-19
Offers Advice On Protecting Participants In Studies For ANDAs
Executive Summary
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
You may also be interested in...
ANDA Guidance Says Yes To Limited Stability Data, No To Expired Reference Product During COVID
US FDA's updated Q&A guidance on developing generics for submission via the abbreviated new drug application pathway during the COVID-19 pandemic has been published.
FDA Updates Guidance On ANDAs During COVID
Updated Q&A guidance on developing generics for submission via the abbreviated new drug application pathway during the COVID-19 pandemic has been published by the FDA.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.